Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea's proprietary in vivo CAR T platform -- Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...
A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...
In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and ...
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety. Read why I am bullish about ...
Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...
With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results